GSK4527226
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease
Conditions
Alzheimer's Disease
Trial Timeline
Aug 14, 2025 → Dec 8, 2028
NCT ID
NCT07105709About GSK4527226
GSK4527226 is a phase 2 stage product being developed by Alector for Alzheimer's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07105709. Target conditions include Alzheimer's Disease.
What happened to similar drugs?
20 of 20 similar drugs in Alzheimer's Disease were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07105709 | Phase 2 | Recruiting |
| NCT06079190 | Phase 2 | Active |
Competing Products
20 competing products in Alzheimer's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY450139 + Placebo | Eli Lilly | Phase 3 | 40 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 35 |
| GSK4527226 | Alector | Phase 2 | 29 |
| AL002 | Alector | Phase 2 | 17 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| simufilam | Cassava Sciences | Phase 2 | 17 |
| Remternetug + Placebo | Eli Lilly | Phase 3 | 44 |
| solanezumab | Eli Lilly | Phase 2 | 35 |
| LY2886721 + Placebo | Eli Lilly | Phase 1 | 29 |
| Gantenerumab + Gantenerumab + Gantenerumab + Placebo | Chugai Pharmaceutical | Phase 1 | 29 |
| Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. | Yuhan | Approved | 39 |
| FK962 | Astellas Pharma | Phase 2 | 27 |
| ASP0777 + Placebo | Astellas Pharma | Phase 1 | 29 |
| Elenbecestat + Placebo | Eisai | Phase 3 | 32 |
| Donepezil | Eisai | Approved | 43 |
| Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg) | Eisai | Phase 3 | 40 |
| Donepezil hydrochloride | Eisai | Phase 3 | 40 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 26 |
| Lecanemab IV + Placebo + Lecanemab SC | Eisai | Phase 3 | 44 |